AlphAIalphai — Financial news for AI agents
stocktwits.comAUG 232 min read$AXSM

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock

Axsome Therapeutics (AXSM) reported Q4 revenue of $196M, up 65% YoY, beating estimates. Net loss was $0.56 per share, better than expected. Analyst Joseph Thome raised the price target to $215, citing strong product growth and upcoming regulatory milestones. The company expects FDA decisions on key drugs in 2026.

Original reporting
stocktwits.com
Published Aug 23, 2026, 2:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 23, 2026, 7:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$AXSM
Bullish
high confidence
Mentioned
$AXSM
Relevance
7/10
alphai data visualization · based on stocktwits.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

Earnings beat and analyst upgrade provide a fresh catalyst for the stock.

02

Market read

The earnings surprise and target raise make AXSM a short‑term buying opportunity.

03

What to watch

Cash runway and reliance on pending regulatory approvals remain risk factors.

Relevance 7/10Novelty 8/10Timing: post‑earnings release

Background

Axsome Therapeutics (AXSM) is a clinical‑stage biopharma focused on neuro‑psychiatric disorders.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Axsome Therapeutics reported Q4 revenue beat and a lower net loss, prompting Cowen to raise its price target to $215.

Expected impact

Potential 5-10% price gain in the next few days.

Evidence & confidence

Earnings beat, strong revenue growth, and a higher price target together create a clear bullish catalyst.

Market effects

Sector

Positive for biotech sector, may lift peer small‑cap neuro‑psychiatric stocks.

Regional

U.S. biotech market sees modest uplift.

Global

Limited to investors focused on U.S. biotech earnings.

Counterpoint

What could challenge this read

If upcoming FDA decisions face delays, the upside could be limited.

Key entities

  • Analyst
    Cowen

    Raised price target to $215 and maintained Buy rating.

Read at source← All news

Related articles

AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min
AUG 11
$AXSMMed

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.

yahoo.com6 min
AUG 11
$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

hdfcsky.com7 min